&w=3840&q=100)
Stocks to buy today: M&M, Titan among top picks recommended by analyst
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
34 minutes ago
- Mint
Nestle India, M&M to Axis Band: 10 key stocks to trade ex-dividend today
Dividend Stocks: Nestle India, M&M, Axis Bank, Bharat Forge, Biocon, Central Bank, Escorts, Tech Mahindra, DCB Bank, and Mac Healthcare are the 10 key stocks to trade ex-dividend today These companies had fixed 4 July 2025 as the record date for identifying the list of the eligible shareholders to receive the dividend announced by these companies. According to the T+1 settlement procedure, investors who intended to get dividends from JSW Infrastructure and Polychem had to buy shares at least one day before the record date. BHARATFORG Final Dividend—The company had recommended a final dividend of Rs. 6.00 per equity share with a face value of Rs. 2.00 each for the financial year that ended on March 31, 2025. AXISBANK Final Dividend—For the financial year that concluded on March 31, 2025, Axis Bank had recommended a final dividend of Re. 1/- per equity share (face value of Rs. 2/- apiece), which is 50% of the face value. Mahindra & Mahindra Ltd., or M&M, had declared a dividend of ₹ 25.30 per share with 4 July as the record date. BIOCON—Biocon Ltd. had recommended a final dividend of ₹ 0.50 with 4 July as the record date. Nestle India Ltd.—NESTLEIND had recommended a final dividend of Rs. 10,000 per equity share. Escorts Kubota Ltd.—ESCORTS had recommended the final dividend of Rs. 18/- (180%) per fully paid-up equity share of Rs. 10/- each. With this, the total dividend (including the interim dividend) for the financial year would be Rs. 28/- (280%) per fully paid-up equity share of Rs. 10/- each Tech Mahindra Ltd., or TECHM, had recommended a final dividend of ₹ 30.00 per share. CENTRALBK, or Central Bank of India, had recommended a final dividend of Rs. 0.1875 per share Max Healthcare Institute Ltd., or MAXHEALTH, had declared a final Dividend of ₹ 1.50 per share. DCB Bank Ltd., or DCBBANK, had declared a Final Dividend of ₹ 1.35 per equity share Among other companies that also declared dividends are Control Print Ltd., or CONTROLPR, had recommended a final dividend of Rs. 6.0000. DBOL, or Dhampir Bio Organics Ltd., had recommended a final dividend of Rs. 1.25. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies and not of Mint. We advise investors to check with certified experts before making any investment decisions.
&w=3840&q=100)
Business Standard
2 hours ago
- Business Standard
F&O Strategy: Bull Spread trades on Nifty Midcap, Biocon explained
Analyst at HDFC Securities have recommended a 'Bear Spread' Strategy on the Nifty MidCap index as it has broken out from the downward sloping trendline on the weekly charts Nandish Shah Mumbai Bull Spread strategy on MIDCP NIFTY Buy MIDCP NIFTY (31-July Expiry) 13,500 Call at ₹261 and simultaneously sell 13,700 Call at ₹165 Lot size: 140 Cost of the strategy: ₹96 (₹13,440 per strategy) Maximum profit: ₹14,560, if MIDCP NIFTY closes at or above 13,700 on 31 July expiry. Breakeven point: ₹13,596 Risk reward ratio: 1: 1.10 Approx margin required: ₹38,000 Rationale: Long build-up is seen in the MIDCP NIFTY futures during the series till now, where open interest has risen by 3 per cent, with it rising by 1 per cent. The primary trend of the MIDCP NIFTY is positive as it is placed above its 50 and 100-day EMAs. It has been forming a bullish higher top, higher bottom formation on the daily chart. It has broken out from the downward sloping trendline on the weekly charts. The short-term trend of the index is positive as it is placed above its 5,11, and 20-day EMAs. Bull Spread strategy on Biocon Buy Biocon (31-July Expiry) 380 Call at ₹9.4 and simultaneously sell 390 Call at ₹5.9 Lot size: 2500 Cost of strategy: ₹3.5 (₹8750 per strategy) Maximum profit: ₹16,250, if Bioson closes at or above ₹390 on 31 July expiry. Breakeven point: ₹383.5 Risk reward ratio: 1:1.86 Approx margin required: ₹33,000 Rationale: Long build-up is seen in the Biocon Futures during the July series till now, where we have seen a 5 per cent rise in open interest with price rising by 7 per cent. Short-term trend remains positive, as the stock price is placed above its 5,11 and 20 day EMAs. The stock price has been forming a bullish higher top, higher bottom formation on the daily chart. RSI and MFI oscillators are in rising mode and placed above 60 on the daily chart, indicating strength in the current uptrend.
Time of India
2 hours ago
- Time of India
Emcure Pharma shares in focus as Bain Capital likely to offload 2.4% stake via block deal
Emcure Pharmaceuticals shares will be in focus on Friday following reports that Bain Capital-affiliated entity BC Investments IV is likely to offload a 2.4% stake in the company via a block deal worth Rs 551 crore. The transaction will involve 45.5 lakh shares at a floor price of Rs 1,279.80 apiece, marginally below Thursday's close of Rs 1,280.30. Kotak Securities is acting as the lead manager for the deal, sources told media outlets. Also Read: Suzlon, Adani Ports among 10 stocks that earned upgrades in last 1 month. Check revised target price Emcure reported a 63% year-on-year jump in consolidated net profit to Rs 197 crore for the March quarter, while revenue rose 19.5% YoY to Rs 2,116 crore, driven by strong performance in both domestic and international markets. Despite the robust financials, the stock has seen muted action recently. Emcure shares are down 4% in the past month and nearly 13% year-to-date (YTD). The stock is trading 19% below its all-time high of Rs 1,580, hit in September 2024. Emcure listed in July 2024, raising Rs 1,952 crore through an IPO, which included a fresh issue of Rs 800 crore and an OFS of Rs 1,151 crore. Priced at Rs 1,008 per share, the stock currently trades about 27% above its IPO price. Also Read: 10 Nifty smallcaps with up to 29 buy calls; analysts see up to 26% upside Emcure Pharma share price target According to Trendlyne, the average target price for Emcure Pharma is Rs 1,458, implying an upside of 14% from current levels. Among the three analysts covering the stock, the consensus rating is 'Buy'. The stock's Relative Strength Index (RSI) stands at 47.6, indicating neutral momentum. It trades above its 50-day, 100-day, and 200-day moving averages, but remains below its 20-day and 30-day SMAs. ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
